Please ensure Javascript is enabled for purposes of website accessibility

Morning Dow Report: Factory Data, Telecom Price Wars Spell Trouble Despite Pfizer Success

By Dan Caplinger – Feb 3, 2014 at 11:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

February isn't starting any better for the Dow than January did. Find out why stocks are falling again today.

Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing thesis.

After a terrible January, investors had hoped to put a bad month behind them and start carving out new gains. But with the latest economic data showing a slowdown in U.S. manufacturing activity, the Dow Jones Industrials (^DJI -0.90%) didn't cooperate with that plan, starting out February with a 150-point drop as of 11 a.m. EST. Telecom stocks AT&T (T -0.16%) and Verizon (VZ 0.81%) led the way down in a broad decline among most Dow components, and Pfizer (PFE -0.12%) was the sole blue-chip component to post anything more than a minimal gain.

AT&T and Verizon both lost about 3% as AT&T offered new lower rates for high-data cell phone rate plans. Specifically, the new pricing applies to AT&T's shared 10-gigabyte monthly plans, and the company estimates savings at $40 to $100 monthly for family or small-business plans that cover four smartphones. The move could encourage some customers to upgrade, paying less than they would for four-gigabyte or six-gigabyte plans. But it also represents a departure for the wireless industry, which has historically relied on its highest-use customers to provide high-margin revenue. Investors are anxiously waiting to see whether Verizon will respond in kind, which seems likely given the direct assault that AT&T makes on Verizon's pricing scheme in its press release.

Pfizer bucked the downtrend, soaring 3.7% after announcing strong results in its PALOMA-1 study of breast-cancer drug palbociclib. The company said the drug met its primary endpoint of improving progression-free survival in advanced breast cancer among post-menopausal women. Even though the study is just a phase 2 trial, palbociclib received breakthrough-therapy status, giving it the potential for an accelerated approval process. Pfizer is starting to enroll patients for a phase 3 trial of the drug.

Given that many investors make monthly contributions toward their investment accounts, the first day of the month is often seen as having a positive bias. If the Dow doesn't recover today, it could be another warning sign that short-term traders in particular will pay attention to in charting their trading course for February.

Dan Caplinger has no position in any stocks mentioned. You can follow him on Twitter @DanCaplinger. The Motley Fool has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Stocks Mentioned

Dow Jones Industrial Average (Price Return) Stock Quote
Dow Jones Industrial Average (Price Return)
$33,476.46 (-0.90%) $-305.02
AT&T Stock Quote
$19.09 (-0.16%) $0.03
Pfizer Stock Quote
$51.72 (-0.12%) $0.06
Verizon Communications Stock Quote
Verizon Communications
$37.40 (0.81%) $0.30

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.